Booster Therapeutics, a Berlin, Germany-based biotechnology company developing a new class of proteasome activator medicines, raised $15M in Seed funding.
The round was led by Apollo Health Ventures and Novo Holdings.
Novo Holdings will play a central role in helping to further build Booster in its next phase of growth, bringing hands-on operational expertise, strategic guidance and helping the company access a network of talent. Novo Holdings will further leverage the expertise in its group of entrepreneurs-in-residence, as well as the Seed Lab wet-lab capabilities in Copenhagen, Denmark.
Founded by Dr. Diogo Feleciano and Dr. Darci Trader, Booster Therapeutics is advancing a new class of medicines that activate the cell’s natural quality control machinery to treat a range of complex indications. Its small molecule therapeutics, discovered through the DGRADX™ platform, are designed to directly boost the activity of 20S proteasomes to restore the body’s ability to clear disease-causing proteins. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function such as Parkinson’s disease and Alzheimer’s disease.
FinSMEs
10/10/2024